prikaz prve stranice dokumenta Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines
  Download
PDF 857.66 KB
Scientific paper - Original scientific paper
Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines
Journal of Medical Virology, 94 (2022), 6; 2849-2854. https://doi.org/10.1002/jmv.27666
Bušić, Nikolina; Lucijanić, Tomo; Baršić, Bruno; Lukšić, Ivica; Bušić, Iva; Kurdija, Goran; Barbić, Ljubo; Kunštek, Sanja; Jelić, Tea; Lucijanić, Marko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Bušić, N., Lucijanić, T., Baršić, B., Lukšić, I., Bušić, I., Kurdija, G. ... Lucijanić, M. (2022). Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines. Journal of Medical Virology, 94. (6), 2849-2854. doi: 10.1002/jmv.27666

Bušić, Nikolina, et al. "Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines." Journal of Medical Virology, vol. 94, no. 6, 2022, pp. 2849-2854. https://doi.org/10.1002/jmv.27666

Bušić, Nikolina, Tomo Lucijanić, Bruno Baršić, Ivica Lukšić, Iva Bušić, Goran Kurdija, Ljubo Barbić, Sanja Kunštek, Tea Jelić and Marko Lucijanić. "Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines." Journal of Medical Virology 94, no. 6 (2022): 2849-2854. https://doi.org/10.1002/jmv.27666

Bušić, N., et al. (2022) 'Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines', Journal of Medical Virology, 94(6), pp. 2849-2854. doi: 10.1002/jmv.27666

Bušić N, Lucijanić T, Baršić B, Lukšić I, Bušić I, Kurdija G, and sur.. Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines. Journal of Medical Virology [Internet]. 2022 June [cited 2024 November 23];94(6):2849-2854. doi: 10.1002/jmv.27666

N. Bušić, et al., "Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines", Journal of Medical Virology, vol. 94, no. 6, pp. 2849-2854, June 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:303609. [Accessed: 23 November 2024]

Metadata
Title (english)Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines
AuthorNikolina Bušić
AuthorTomo Lucijanić
AuthorBruno Baršić
AuthorIvica Lukšić
AuthorIva Bušić
AuthorGoran Kurdija
AuthorLjubo Barbić
AuthorSanja Kunštek
AuthorTea Jelić
AuthorMarko Lucijanić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Maxillofacial Surgery and Dentistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Surgery
Abstract (english)
Outcomes of 109 hospitalized COVID-19 patients who received at least one vaccine dose 14 or more days prior the disease onset were retrospectively compared to control cohort of 109 age, sex, and Charlson comorbidity index-matched patients chosen among 2990 total hospitalized patients in our tertiary-level institution in a period from January to June 2021. Among 109 vaccinated patients, 84 patients were partially and 25 fully vaccinated. Vaccinated patients experienced significantly lower 30 days mortality (30% vs. 49%; hazard ratio [HR]: 0.56 [0.37-0.85]; p = 0.008), less frequently required high flow oxygen therapy (17% vs. 34%; HR: 0.45 [0.26-0.76]; p = 0.005), and mechanical ventilation (8% vs. 18%; HR: 0.41 [0.20-0.88]; p = 0.027) in comparison to the matched cohort of unvaccinated patients. More favorable survival was observed in patients receiving vector in comparison to messenger RNA (mRNA) vaccine types in unadjusted analysis (30 days mortality 18% vs. 40%; HR: 0.45 [0.25-0.79]; p = 0.034). In the multivariable Cox regression analysis model both mRNA (HR: 0.59 [0.36-0.98]; p = 0.041) and vector vaccine types (HR: 0.30 [0.15-0.60]; p < 0.001) were associated with improved survival in comparison to unvaccinated patients, independently of age (HR: 1.03 [1.01-1.06]; p = 0.011), male sex (HR: 1.78 [1.14-2.76]; p = 0.010), severity of illness (HR: 2.06 [1.36-3.10]; p < 0.001) and functional status on admission (HR: 1.42 [1.07-1.85]; p = 0.013).
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Medical Virology
Numberingvol. 94, no. 6, pp. 2849-2854
p-ISSN0146-6615
e-ISSN1096-9071
DOIhttps://doi.org/10.1002/jmv.27666
URN:NBNurn:nbn:hr:105:303609
Publication2022-06
Document URLhttps://onlinelibrary.wiley.com/doi/10.1002/jmv.27666
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-07-19 10:06:18